Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Keros Therapeutics, Inc. (KROS : NSDQ)

• Company Description    Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics, Inc. is based in LEXINGTON, MA. Number of Employees: 169

• Price / Volume Information    Yesterday's Closing Price: $21.36 Daily Weekly Monthly 20 Day Moving Average: 774,595 shares Shares Outstanding: 30.47 (millions) Market Capitalization: $650.76 (millions) Beta: 0.89 52 Week High: $22.55 52 Week Low: $9.12 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 22.06% 19.95% 12 Week 39.79% 35.34% Year To Date 34.93% 14.49%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1050 WALTHAM STREET SUITE 302 - LEXINGTON,MA 02421 USA ph: 617-314-6297 fax: - jfrantz@kerostx.com http://www.kerostx.com

• General Corporate Information    Officers Jasbir Seehra - Chief Executive Officer Keith Regnante - Chief Financial Officer Jean-Jacques Bienaime - Director Nima Farzan - Director Carl Gordon - Director Peer Information Keros Therapeutics, Inc. (CORR.) Keros Therapeutics, Inc. (RSPI) Keros Therapeutics, Inc. (CGXP) Keros Therapeutics, Inc. (BGEN) Keros Therapeutics, Inc. (GTBP) Keros Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 492327101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/25/26 Share - Related Items Shares Outstanding: 30.47 Most Recent Split Date: (:1) Beta: 0.89 Market Capitalization: $650.76 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.49 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $2.25 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 36.50% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/25/26

• Fundamental Ratios P/E Current FY Estimate: 9.49 Trailing 12 Months: 13.87 PEG Ratio: 0.26 Price Ratios Price/Book: 0.92 Price/Cash Flow: - Price / Sales: 2.64 EPS Growth vs. Year Ago Period: 87.23% vs. Previous Quarter: 76.32% Sales Growth vs. Year Ago Period: 3,575.77% vs. Previous Quarter: -21.50% ROE 09/30/25 - 9.51 06/30/25 - 2.96 03/31/25 - 0.75 ROA 09/30/25 - 8.89 06/30/25 - 2.74 03/31/25 - 0.69 Current Ratio 09/30/25 - 29.86 06/30/25 - 21.11 03/31/25 - 19.29 Quick Ratio 09/30/25 - 29.86 06/30/25 - 21.11 03/31/25 - 19.29 Operating Margin 09/30/25 - 26.12 06/30/25 - 8.06 03/31/25 - 1.96 Net Margin 09/30/25 - 26.12 06/30/25 - 8.06 03/31/25 - 1.96 Pre-Tax Margin 09/30/25 - 28.84 06/30/25 - 11.55 03/31/25 - 6.78 Book Value 09/30/25 - 23.09 06/30/25 - 17.40 03/31/25 - 17.95 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©